Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Kaan KumruDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Zi YaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Brandon B HolmesDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158.
Fangzhu ZhaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.ORCID 0000-0002-3172-1340
Yun ZhangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Emilio FerraraDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94158.
Trenton M Peters-ClarkeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.ORCID 0000-0002-2087-4974
James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158.ORCID 0000-0001-8267-5519
Funding
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
UCSF/UCB Joint Graduate Group in BioengineeringT32GM139794 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DANIEL A FLETCHER, Christopher John Hernandez · 2021 to 2026
$5.2M
New protein engineering-based tools and technologies for characterizing cell surface proteolysis in cancer cells for novel neo-epitope biomarkers and drug targetsR01CA248323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2020 to 2026
$2.6M
Interrogating and Targeting Microglia Phagocytosis in Alzheimer’s DiseaseK08NS133290 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brandon Blake Holmes · 2023 to 2026
$837k
Toward Understanding the Functional Landscape of Proteolysis at the Cell SurfaceF32CA298768 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trenton Peters-Clarke · 2025 to 2026
$155k
Mapping tumor specific immunopeptidome for antibody-based targeted therapyF32GM149084 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YAO, ZI · 2023 to 2024
$143k
A.P. Giannini Foundation (APGF) FellowshipHHS | NIH | National Cancer Institute (NCI) 1R01CA248323-01HHS | NIH | National Cancer Institute (NCI) F32CA298768HHS | NIH | National Institute of General Medical Sciences (NIGMS) 1R35GM122451-01HHS | NIH | National Institute of General Medical Sciences (NIGMS) 5F32GM149084-02HHS | NIH | National Institute of General Medical Sciences (NIGMS) 5T32GM139794-05HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) 1K08NS133290-01NCI NIH HHS F32 CA298768NCI NIH HHS R01 CA248323NIGMS NIH HHS F32 GM149084NIGMS NIH HHS R35 GM122451NIGMS NIH HHS T32 GM139794NINDS NIH HHS K08 NS133290NSF | NSF Graduate Research Fellowship Program (GRFP) 2022340436
6 · The paper itself
Abstract
Extracellular targeted protein degradation (eTPD) is an important new modality for manipulating the extracellular proteome. However, most eTPD receptors are expressed broadly or are restricted to the liver, limiting specific degradation in other tissues. Cytokine receptor-targeting chimeras (kineTACs) are genetically encoded bispecifics for eTPD that fuse a natural ligand like CXCL12 to an antibody, directing soluble or membrane proteins for lysosomal degradation using the widely expressed chemokine receptor CXCR7 (K. Pance
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
A cytokine receptor-targeting chimera toolbox for expanding extracellular targeted protein degradation. · full record | Socratic